Price Disclosure Reductions for 2015 October Cycle
Page last updated: 17 September 2015
This summary of 1 October 2015 price disclosure reductions for the 2015 October Cycle only includes medicines taking a reduction. The price disclosure legal determination mentioned at the bottom of this page includes brands with no reductions (see Schedule 2 of the determination).
The price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 1960 (the Regulations) in place as at June 2015.
The outcomes below show % price differences and ex-manufacturer level prices. They do not include fees and mark-ups.
Indicative prices for 1 October 2015 (including price to pharmacy, Dispensed Price for Maximum Quantity and price premiums) will be published by mid to late July 2015. Subscribe to PBS News to receive notice when they become available.
Final prices for 1 October 2015 (including all price to pharmacy, Dispensed Price for Maximum Quantity/Amount and price premiums) will be available from early September 2015.
| Legal Instrument Drug | Legal Instrument MoA | Legal Instrument Form | Average AEMP ($) |
WAPD (%) across a drug/MoA |
WADP - potential October 15 PBS Price (AEMP) ($) per pharmaceutical item |
April 15 AEMP ($) |
Percentage difference between April 15 and October 15 PBS prices (AEMP) (%) per pharmaceutical item |
|---|---|---|---|---|---|---|---|
| [Average AEMP minus WAPD = WADP] | [Difference between April AEMP & WADP = % Difference] |
||||||
| Aciclovir | Oral | Tablet 200 mg | 10.38 | 20.01% | 8.30 | 10.38 | 20.04% |
| Aciclovir | Oral | Tablet 800 mg | 45.19 | 20.01% | 36.15 | 45.19 | 20.00% |
| Acitretin | Oral | Capsule 10 mg | 141.68 | 12.25% | 124.32 | 141.68 | 12.25% |
| Acitretin | Oral | Capsule 25 mg | 288.12 | 12.25% | 252.83 | 288.12 | 12.25% |
| Alendronic acid | Oral | Tablet 70 mg (as alendronate sodium) | 6.60 | 30.91% | 4.56 | 5.86 | 22.18% |
| Alendronic acid with colecalciferol | Oral | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | 31.85 | 15.52% | 26.91 | 31.85 | 15.51% |
| Alendronic acid with colecalciferol | Oral | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | 31.85 | 15.52% | 26.91 | 31.85 | 15.51% |
| Amlodipine with atorvastatin | Oral | Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium) | 31.98 | 20.09% | 25.56 | 31.98 | 20.08% |
| Amlodipine with atorvastatin | Oral | Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium) | 43.78 | 20.09% | 34.98 | 43.78 | 20.10% |
| Amlodipine with atorvastatin | Oral | Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium) | 58.73 | 20.09% | 46.93 | 58.73 | 20.09% |
| Amlodipine with atorvastatin | Oral | Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium) | 80.89 | 20.09% | 64.64 | 80.89 | 20.09% |
| Amlodipine with atorvastatin | Oral | Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium) | 28.91 | 20.09% | 23.10 | 28.91 | 20.10% |
| Amlodipine with atorvastatin | Oral | Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium) | 40.71 | 20.09% | 32.53 | 40.71 | 20.09% |
| Amlodipine with atorvastatin | Oral | Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium) | 55.66 | 20.09% | 44.48 | 55.66 | 20.09% |
| Amlodipine with atorvastatin | Oral | Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium) | 77.82 | 20.09% | 62.19 | 77.82 | 20.08% |
| Ampicillin | Injection | Powder for injection 1 g (as sodium) | 5.23 | 13.82% | 4.51 | 5.23 | 13.77% |
| Ampicillin | Injection | Powder for injection 500 mg (as sodium) | 3.18 | 13.82% | 2.74 | 3.18 | 13.84% |
| Anastrozole | Oral | Tablet 1 mg | 76.50 | 27.15% | 55.73 | 66.65 | 16.38% |
| Atorvastatin | Oral | Tablet 10 mg (as calcium) | 5.03 | 44.78% | 2.78 | 3.76 | 26.06% |
| Atorvastatin | Oral | Tablet 20 mg (as calcium) | 7.42 | 44.78% | 4.10 | 5.55 | 26.13% |
| Atorvastatin | Oral | Tablet 40 mg (as calcium) | 10.45 | 44.78% | 5.77 | 7.82 | 26.21% |
| Atorvastatin | Oral | Tablet 80 mg (as calcium) | 14.94 | 44.78% | 8.25 | 11.18 | 26.21% |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 10 mg | 25.87 | 27.79% | 18.68 | 21.89 | 14.66% |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 2.5 mg | 16.56 | 27.79% | 11.96 | 14.01 | 14.63% |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 5 mg | 20.69 | 27.79% | 14.94 | 17.51 | 14.68% |
| Calcitriol | Oral | Capsule 0.25 microgram | 19.30 | 11.29% | 17.12 | 19.30 | 11.30% |
| Candesartan | Oral | Tablet containing candesartan cilexetil 16 mg | 12.54 | 37.39% | 7.85 | 9.88 | 20.55% |
| Candesartan | Oral | Tablet containing candesartan cilexetil 32 mg | 15.16 | 37.39% | 9.49 | 11.94 | 20.52% |
| Candesartan | Oral | Tablet containing candesartan cilexetil 4 mg | 1.40 | 37.39% | 0.88 | 1.11 | 20.72% |
| Candesartan | Oral | Tablet containing candesartan cilexetil 8 mg | 4.19 | 37.39% | 2.62 | 3.30 | 20.61% |
| Candesartan with hydrochlorothiazide | Oral | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | 13.00 | 31.08% | 8.96 | 13.00 | 31.08% |
| Candesartan with hydrochlorothiazide | Oral | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | 15.47 | 31.08% | 10.66 | 15.47 | 31.09% |
| Candesartan with hydrochlorothiazide | Oral | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | 16.64 | 31.08% | 11.47 | 16.64 | 31.07% |
| Capecitabine | Oral | Tablet 150 mg | 83.46 | 52.03% | 40.04 | 83.46 | 52.02% |
| Capecitabine | Oral | Tablet 500 mg | 517.39 | 52.03% | 248.19 | 517.39 | 52.03% |
| Cephalexin | Oral | Capsule 250 mg (anhydrous) | 0.91 | 10.74% | 0.81 | 0.91 | 10.99% |
| Cephalexin | Oral | Capsule 500 mg (anhydrous) | 1.64 | 10.74% | 1.46 | 1.64 | 10.98% |
| Cephalexin | Oral | Granules for oral suspension 125 mg per 5 mL, 100 mL | 1.09 | 10.74% | 0.97 | 1.09 | 11.01% |
| Cephalexin | Oral | Granules for oral suspension 250 mg per 5 mL, 100 mL | 1.62 | 10.74% | 1.45 | 1.62 | 10.49% |
| Ciprofloxacin | Oral | Tablet 250 mg (as hydrochloride) | 4.41 | 18.46% | 3.60 | 4.41 | 18.37% |
| Ciprofloxacin | Oral | Tablet 500 mg (as hydrochloride) | 8.62 | 18.46% | 7.03 | 8.62 | 18.45% |
| Ciprofloxacin | Oral | Tablet 750 mg (as hydrochloride) | 13.00 | 18.46% | 10.60 | 13.00 | 18.46% |
| Citalopram | Oral | Tablet 10 mg (as hydrobromide) | 1.32 | 19.98% | 1.06 | 1.32 | 19.70% |
| Citalopram | Oral | Tablet 20 mg (as hydrobromide) | 2.00 | 19.98% | 1.60 | 2.00 | 20.00% |
| Citalopram | Oral | Tablet 40 mg (as hydrobromide) | 3.39 | 19.98% | 2.71 | 3.39 | 20.06% |
| Clarithromycin | Oral | Tablet 250 mg | 2.80 | 11.78% | 2.47 | 2.80 | 11.79% |
| Clarithromycin | Oral | Tablet 500 mg | 39.93 | 11.78% | 35.23 | 39.93 | 11.77% |
| Cromoglycic acid | Application to the eye | Eye drops containing sodium cromoglycate 20 mg per mL, 10 mL | 6.30 | 19.68% | 5.06 | 6.30 | 19.68% |
| Dexamethasone | Injection | Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL | 5.49 | 10.70% | 4.90 | 9.06 | 45.92% |
| Dexamethasone | Injection | Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL | 9.98 | 10.70% | 8.91 | 14.97 | 40.48% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 140 mg in 7 mL | 48.11 | 44.28% | 26.81 | 30.37 | 11.72% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 160 mg in 16 mL | 55.22 | 44.28% | 30.77 | 34.85 | 11.71% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 20 mg in 1 mL | 6.89 | 44.28% | 3.84 | 4.35 | 11.72% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 20 mg in 2 mL | 6.89 | 44.28% | 3.84 | 4.35 | 11.72% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 80 mg in 4 mL | 27.61 | 44.28% | 15.38 | 17.43 | 11.76% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 80 mg in 8 mL | 27.61 | 44.28% | 15.38 | 17.43 | 11.76% |
| Donepezil | Oral | Tablet containing donepezil hydrochloride 10 mg | 26.59 | 33.84% | 17.59 | 26.59 | 33.85% |
| Donepezil | Oral | Tablet containing donepezil hydrochloride 5 mg | 26.59 | 33.84% | 17.59 | 26.59 | 33.85% |
| Doxorubicin - pegylated liposomal | Injection | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | 523.31 | 18.74% | 425.24 | 523.31 | 18.74% |
| Doxorubicin - pegylated liposomal | Injection | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | 1245.97 | 18.74% | 1,012.48 | 1,245.97 | 18.74% |
| Duloxetine | Oral | Capsule 30 mg (as hydrochloride) | 13.86 | 46.13% | 7.47 | 9.66 | 22.67% |
| Duloxetine | Oral | Capsule 60 mg (as hydrochloride) | 19.80 | 46.13% | 10.67 | 13.79 | 22.63% |
| Enalapril with hydrochlorothiazide | Oral | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | 17.13 | 12.30% | 15.02 | 17.13 | 12.32% |
| Famciclovir | Oral | Tablet 125 mg | 55.09 | 34.26% | 36.22 | 42.50 | 14.78% |
| Famciclovir | Oral | Tablet 250 mg | 55.10 | 34.26% | 36.22 | 42.50 | 14.78% |
| Famciclovir | Oral | Tablet 500 mg | 82.64 | 34.26% | 54.33 | 63.75 | 14.78% |
| Famotidine | Oral | Tablet 20 mg | 4.07 | 12.15% | 3.58 | 4.07 | 12.04% |
| Famotidine | Oral | Tablet 40 mg | 4.07 | 12.15% | 3.58 | 4.07 | 12.04% |
| Filgrastim | Injection | Injection 120 micrograms in 0.2 mL single use pre-filled syringe (Nivestim) | 426.64 | 22.63% | 330.09 | 426.64 | 22.63% |
| Filgrastim | Injection | Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Neupogen) | 1066.59 | 22.63% | 825.22 | 1,066.59 | 22.63% |
| Filgrastim | Injection | Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim) | 1066.59 | 22.63% | 825.22 | 1,066.59 | 22.63% |
| Filgrastim | Injection | Injection 300 micrograms in 0.5 mL single use pre-filled syringe (TevaGrastim) | 1066.59 | 22.63% | 825.22 | 1,066.59 | 22.63% |
| Filgrastim | Injection | Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Zarzio) | 533.29 | 22.63% | 412.61 | 533.29 | 22.63% |
| Filgrastim | Injection | Injection 300 micrograms in 1 mL | 1066.59 | 22.63% | 825.22 | 1,066.59 | 22.63% |
| Filgrastim | Injection | Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Neupogen) | 1709.81 | 22.63% | 1,322.88 | 1,709.81 | 22.63% |
| Filgrastim | Injection | Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim) | 1709.81 | 22.63% | 1,322.88 | 1,709.81 | 22.63% |
| Filgrastim | Injection | Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Zarzio) | 854.90 | 22.63% | 661.44 | 854.90 | 22.63% |
| Filgrastim | Injection | Injection 480 micrograms in 0.8 mL single use pre-filled syringe (TevaGrastim) | 1709.81 | 22.63% | 1,322.88 | 1,709.81 | 22.63% |
| Filgrastim | Injection | Injection 480 micrograms in 1.6 mL | 1709.81 | 22.63% | 1,322.88 | 1,709.81 | 22.63% |
| Fluconazole | Oral | Capsule 100 mg | 30.47 | 13.70% | 26.30 | 30.47 | 13.69% |
| Fluconazole | Oral | Capsule 200 mg | 59.36 | 13.70% | 51.23 | 59.36 | 13.70% |
| Fluconazole | Oral | Capsule 50 mg | 15.65 | 13.70% | 13.51 | 15.65 | 13.67% |
| Fluconazole | Injection | Solution for I.V. infusion 100 mg in 50 mL | 1.82 | 18.06% | 1.49 | 1.82 | 18.13% |
| Fluconazole | Injection | Solution for I.V. infusion 200 mg in 100 mL | 3.43 | 18.06% | 2.81 | 3.43 | 18.08% |
| Fluconazole | Injection | Solution for I.V. infusion 400 mg in 200 mL | 5.39 | 18.06% | 4.42 | 5.39 | 18.00% |
| Frusemide | Injection | Injection 20 mg in 2 mL | 1.52 | 10.75% | 1.36 | 1.52 | 10.53% |
| Galantamine | Oral | Capsule (prolonged release) 16 mg (as hydrobromide) | 37.15 | 13.61% | 32.09 | 37.15 | 13.62% |
| Galantamine | Oral | Capsule (prolonged release) 24 mg (as hydrobromide) | 44.27 | 13.61% | 38.24 | 44.27 | 13.62% |
| Galantamine | Oral | Capsule (prolonged release) 8 mg (as hydrobromide) | 30.37 | 13.61% | 26.24 | 30.37 | 13.60% |
| Gemcitabine | Injection | Powder for I.V. infusion 1 g (as hydrochloride) | 16.69 | 20.38% | 13.29 | 16.69 | 20.37% |
| Gemcitabine | Injection | Powder for I.V. infusion 2 g (as hydrochloride) | 33.45 | 20.38% | 26.63 | 33.45 | 20.39% |
| Gemcitabine | Injection | Powder for I.V. infusion 200 mg (as hydrochloride) | 3.38 | 20.38% | 2.69 | 3.38 | 20.41% |
| Gemcitabine | Injection | Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL | 16.69 | 20.38% | 13.29 | 16.69 | 20.37% |
| Gemcitabine | Injection | Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL | 3.38 | 20.38% | 2.69 | 3.38 | 20.41% |
| Gemcitabine | Injection | Solution concentrate for I.V. infusion 500 mg (as hydrochloride) in 50 mL | 8.35 | 20.38% | 6.65 | 8.35 | 20.36% |
| Gemcitabine | Injection | Solution for injection 1 g (as hydrochloride) in 26.3 mL | 16.69 | 20.38% | 13.29 | 16.69 | 20.37% |
| Gemcitabine | Injection | Solution for injection 2 g (as hydrochloride) in 52.6 mL | 33.45 | 20.38% | 26.63 | 33.45 | 20.39% |
| Gemcitabine | Injection | Solution for injection 200 mg (as hydrochloride) in 5.3 mL | 3.38 | 20.38% | 2.69 | 3.38 | 20.41% |
| Glimepiride | Oral | Tablet 1 mg | 1.15 | 11.35% | 1.02 | 1.15 | 11.30% |
| Glimepiride | Oral | Tablet 2 mg | 2.20 | 11.35% | 1.95 | 2.20 | 11.36% |
| Glimepiride | Oral | Tablet 3 mg | 2.80 | 11.35% | 2.48 | 2.80 | 11.43% |
| Glimepiride | Oral | Tablet 4 mg | 3.44 | 11.35% | 3.05 | 3.44 | 11.34% |
| Glucose | Injection | I.V. infusion 278 mmol (anhydrous) per L, 1 L | 1.67 | 21.56% | 1.31 | 1.49 | 12.08% |
| Granisetron | Injection | Concentrated injection 3 mg (as hydrochloride) in 3 mL | 3.98 | 26.49% | 2.93 | 3.98 | 26.38% |
| Idarubicin | Injection | Solution for I.V. injection containing idarubicin hydrochloride 10 mg in 10 mL | 148.55 | 41.21% | 87.33 | 119.41 | 26.87% |
| Idarubicin | Injection | Solution for I.V. injection containing idarubicin hydrochloride 5 mg in 5 mL | 76.83 | 41.21% | 45.17 | 61.76 | 26.86% |
| Imiquimod | Application | Cream 50 mg per g, 2 g, 2 | 109.04 | 23.78% | 83.11 | 109.04 | 23.78% |
| Imiquimod | Application | Cream 50 mg per g, 250 mg single use sachets, 12 | 109.04 | 23.78% | 83.11 | 109.04 | 23.78% |
| Irbesartan | Oral | Tablet 150 mg | 4.75 | 31.53% | 3.25 | 4.14 | 21.50% |
| Irbesartan | Oral | Tablet 300 mg | 9.49 | 31.53% | 6.50 | 8.27 | 21.40% |
| Irbesartan | Oral | Tablet 75 mg | 3.33 | 31.53% | 2.28 | 2.90 | 21.38% |
| Irbesartan with hydrochlorothiazide | Oral | Tablet 150 mg-12.5 mg | 5.77 | 30.99% | 3.98 | 5.77 | 31.02% |
| Irbesartan with hydrochlorothiazide | Oral | Tablet 300 mg-12.5 mg | 10.59 | 30.99% | 7.31 | 10.59 | 30.97% |
| Irbesartan with hydrochlorothiazide | Oral | Tablet 300 mg-25 mg | 11.53 | 30.99% | 7.96 | 11.53 | 30.96% |
| Iron polymaltose complex | Injection | Injection 100 mg (iron) in 2 mL | 20.31 | 18.05% | 16.64 | 20.31 | 18.07% |
| Isotretinoin | Oral | Capsule 10 mg | 34.02 | 27.13% | 24.79 | 29.79 | 16.78% |
| Isotretinoin | Oral | Capsule 20 mg | 53.02 | 27.13% | 38.64 | 46.42 | 16.76% |
| Isotretinoin | Oral | Capsule 40 mg | 47.86 | 27.13% | 34.88 | 41.90 | 16.75% |
| Letrozole | Oral | Tablet 2.5 mg | 71.66 | 33.19% | 47.88 | 62.29 | 23.13% |
| Memantine | Oral | Tablet containing memantine hydrochloride 10 mg | 51.00 | 14.29% | 43.71 | 51.00 | 14.29% |
| Memantine | Oral | Tablet containing memantine hydrochloride 20 mg | 51.00 | 14.29% | 43.71 | 51.00 | 14.29% |
| Metoprolol | Oral | Tablet containing metoprolol tartrate 100 mg | 2.81 | 10.21% | 2.52 | 2.81 | 10.32% |
| Metoprolol | Oral | Tablet containing metoprolol tartrate 50 mg | 2.20 | 10.21% | 1.98 | 2.20 | 10.00% |
| Montelukast | Oral | Tablet, chewable, 4 mg (as sodium) | 20.43 | 39.35% | 12.39 | 20.43 | 39.35% |
| Montelukast | Oral | Tablet, chewable, 5 mg (as sodium) | 19.21 | 39.35% | 11.65 | 19.21 | 39.35% |
| Mycophenolic acid | Oral | Capsule containing mycophenolate mofetil 250 mg | 45.34 | 21.16% | 35.75 | 45.34 | 21.15% |
| Mycophenolic acid | Oral | Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid | 108.81 | 21.16% | 85.79 | 108.81 | 21.16% |
| Mycophenolic acid | Oral | Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid | 217.61 | 21.16% | 171.56 | 217.61 | 21.16% |
| Mycophenolic acid | Oral | Tablet containing mycophenolate mofetil 500 mg | 90.67 | 21.16% | 71.48 | 90.67 | 21.16% |
| Olanzapine | Oral | Tablet 10 mg | 47.68 | 47.13% | 25.21 | 33.76 | 25.33% |
| Olanzapine | Oral | Tablet 10 mg (as benzoate) | 47.68 | 47.13% | 25.21 | 33.76 | 25.33% |
| Olanzapine | Oral | Tablet 10 mg (orally disintegrating) | 47.68 | 47.13% | 25.21 | 33.76 | 25.33% |
| Olanzapine | Oral | Tablet 15 mg (orally disintegrating) | 71.52 | 47.13% | 37.81 | 50.63 | 25.32% |
| Olanzapine | Oral | Tablet 2.5 mg | 11.92 | 47.13% | 6.30 | 8.44 | 25.36% |
| Olanzapine | Oral | Tablet 2.5 mg (as benzoate) | 11.92 | 47.13% | 6.30 | 8.44 | 25.36% |
| Olanzapine | Oral | Tablet 20 mg (orally disintegrating) | 95.36 | 47.13% | 50.42 | 67.51 | 25.31% |
| Olanzapine | Oral | Tablet 5 mg | 23.60 | 47.13% | 12.48 | 16.71 | 25.31% |
| Olanzapine | Oral | Tablet 5 mg (as benzoate) | 23.60 | 47.13% | 12.48 | 16.71 | 25.31% |
| Olanzapine | Oral | Tablet 5 mg (orally disintegrating) | 23.60 | 47.13% | 12.48 | 16.71 | 25.31% |
| Olanzapine | Oral | Tablet 7.5 mg | 35.77 | 47.13% | 18.91 | 25.32 | 25.32% |
| Olanzapine | Oral | Tablet 7.5 mg (as benzoate) | 35.77 | 47.13% | 18.91 | 25.32 | 25.32% |
| Olanzapine | Oral | Wafer 10 mg | 47.68 | 47.13% | 25.21 | 33.76 | 25.33% |
| Olanzapine | Oral | Wafer 15 mg | 71.52 | 47.13% | 37.81 | 50.63 | 25.32% |
| Olanzapine | Oral | Wafer 20 mg | 95.36 | 47.13% | 50.42 | 67.51 | 25.31% |
| Olanzapine | Oral | Wafer 5 mg | 23.60 | 47.13% | 12.48 | 16.71 | 25.31% |
| Ondansetron | Injection | I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL | 0.90 | 60.05% | 0.36 | 0.59 | 38.98% |
| Ondansetron | Injection | I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL | 1.43 | 60.05% | 0.57 | 0.94 | 39.36% |
| Ondansetron | Oral | Tablet (orally disintegrating) 4 mg | 8.23 | 32.64% | 5.54 | 6.50 | 14.77% |
| Ondansetron | Oral | Tablet (orally disintegrating) 8 mg | 12.89 | 32.64% | 8.68 | 10.18 | 14.73% |
| Ondansetron | Oral | Tablet 4 mg (as hydrochloride dihydrate) | 8.23 | 32.64% | 5.54 | 6.50 | 14.77% |
| Ondansetron | Oral | Tablet 8 mg (as hydrochloride dihydrate) | 12.89 | 32.64% | 8.68 | 10.18 | 14.73% |
| Ondansetron | Oral | Wafer 4 mg | 8.23 | 32.64% | 5.54 | 6.50 | 14.77% |
| Ondansetron | Oral | Wafer 8 mg | 12.89 | 32.64% | 8.68 | 10.18 | 14.73% |
| Pamidronic acid | Injection | Concentrated injection containing disodium pamidronate 15 mg in 5 mL | 20.16 | 23.68% | 15.39 | 17.16 | 10.31% |
| Pamidronic acid | Injection | Concentrated injection containing disodium pamidronate 30 mg in 10 mL | 40.33 | 23.68% | 30.78 | 34.33 | 10.34% |
| Pamidronic acid | Injection | Concentrated injection containing disodium pamidronate 60 mg in 10 mL | 80.64 | 23.68% | 61.54 | 68.65 | 10.36% |
| Pamidronic acid | Injection | Concentrated injection containing disodium pamidronate 90 mg in 10 mL | 120.97 | 23.68% | 92.32 | 102.98 | 10.35% |
| Pamidronic acid | Injection | Injection set containing 1 vial powder for I.V. infusion containing disodium pamidronate 90 mg and 1 ampoule solvent 10 mL | 120.97 | 23.68% | 92.32 | 102.98 | 10.35% |
| Pamidronic acid | Injection | Injection set containing 2 vials powder for I.V. infusion containing disodium pamidronate 30 mg and 2 ampoules solvent 10 mL | 80.65 | 23.68% | 61.55 | 68.66 | 10.36% |
| Quetiapine | Oral | Tablet (modified release) 150 mg (as fumarate) | 51.43 | 32.23% | 34.85 | 45.01 | 22.57% |
| Quetiapine | Oral | Tablet (modified release) 200 mg (as fumarate) | 70.07 | 32.23% | 47.49 | 61.33 | 22.57% |
| Quetiapine | Oral | Tablet (modified release) 300 mg (as fumarate) | 102.81 | 32.23% | 69.67 | 89.99 | 22.58% |
| Quetiapine | Oral | Tablet (modified release) 400 mg (as fumarate) | 140.14 | 32.23% | 94.97 | 122.67 | 22.58% |
| Quetiapine | Oral | Tablet (modified release) 50 mg (as fumarate) | 36.34 | 32.23% | 24.63 | 31.81 | 22.57% |
| Quetiapine | Oral | Tablet 100 mg (as fumarate) | 51.43 | 32.23% | 34.85 | 45.01 | 22.57% |
| Quetiapine | Oral | Tablet 200 mg (as fumarate) | 70.07 | 32.23% | 47.49 | 61.33 | 22.57% |
| Quetiapine | Oral | Tablet 25 mg (as fumarate) | 18.17 | 32.23% | 12.31 | 15.91 | 22.63% |
| Quetiapine | Oral | Tablet 300 mg (as fumarate) | 102.81 | 32.23% | 69.67 | 89.99 | 22.58% |
| Rabeprazole | Oral | Tablet containing rabeprazole sodium 10 mg (enteric coated) | 8.60 | 31.61% | 5.88 | 6.74 | 12.76% |
| Rabeprazole | Oral | Tablet containing rabeprazole sodium 20 mg (enteric coated) | 8.60 | 31.61% | 5.88 | 6.74 | 12.76% |
| Ramipril | Oral | Capsule 1.25 mg | 1.45 | 16.06% | 1.22 | 1.45 | 15.86% |
| Ramipril | Oral | Capsule 10 mg | 4.69 | 16.06% | 3.94 | 4.69 | 15.99% |
| Ramipril | Oral | Capsule 2.5 mg | 2.12 | 16.06% | 1.78 | 2.12 | 16.04% |
| Ramipril | Oral | Capsule 5 mg | 2.66 | 16.06% | 2.23 | 2.66 | 16.17% |
| Ramipril | Oral | Pack containing 7 tablets 2.5 mg, 21 tablets 5 mg and 10 capsules 10 mg | 4.36 | 16.06% | 3.66 | 4.36 | 16.06% |
| Ramipril | Oral | Tablet 1.25 mg | 1.45 | 16.06% | 1.22 | 1.45 | 15.86% |
| Ramipril | Oral | Tablet 10 mg | 4.69 | 16.06% | 3.94 | 4.69 | 15.99% |
| Ramipril | Oral | Tablet 2.5 mg | 2.12 | 16.06% | 1.78 | 2.12 | 16.04% |
| Ramipril | Oral | Tablet 5 mg | 2.66 | 16.06% | 2.23 | 2.66 | 16.17% |
| Risedronic acid | Oral | Tablet (enteric coated) containing risedronate sodium 35 mg | 28.69 | 11.46% | 25.40 | 28.69 | 11.47% |
| Risedronic acid | Oral | Tablet containing risedronate sodium 150 mg | 31.09 | 11.46% | 27.53 | 31.09 | 11.45% |
| Risedronic acid | Oral | Tablet containing risedronate sodium 30 mg | 195.92 | 11.46% | 173.47 | 195.92 | 11.46% |
| Risedronic acid | Oral | Tablet containing risedronate sodium 35 mg | 28.69 | 11.46% | 25.40 | 28.69 | 11.47% |
| Risedronic acid | Oral | Tablet containing risedronate sodium 5 mg | 28.69 | 11.46% | 25.40 | 28.69 | 11.47% |
| Risperidone | Oral | Tablet 0.5 mg | 2.07 | 24.21% | 1.57 | 1.85 | 15.14% |
| Risperidone | Oral | Tablet 0.5 mg (orally disintegrating) | 3.48 | 24.21% | 2.64 | 3.10 | 14.84% |
| Risperidone | Oral | Tablet 1 mg | 11.98 | 24.21% | 9.08 | 10.69 | 15.06% |
| Risperidone | Oral | Tablet 1 mg (orally disintegrating) | 6.95 | 24.21% | 5.27 | 6.21 | 15.14% |
| Risperidone | Oral | Tablet 2 mg | 27.40 | 24.21% | 20.77 | 24.47 | 15.12% |
| Risperidone | Oral | Tablet 2 mg (orally disintegrating) | 13.97 | 24.21% | 10.59 | 12.47 | 15.08% |
| Risperidone | Oral | Tablet 3 mg | 42.25 | 24.21% | 32.02 | 37.73 | 15.13% |
| Risperidone | Oral | Tablet 3 mg (orally disintegrating) | 20.76 | 24.21% | 15.73 | 18.53 | 15.11% |
| Risperidone | Oral | Tablet 4 mg | 57.04 | 24.21% | 43.23 | 50.93 | 15.12% |
| Risperidone | Oral | Tablet 4 mg (orally disintegrating) | 27.65 | 24.21% | 20.96 | 24.70 | 15.14% |
| Rosuvastatin | Oral | Tablet 10 mg (as calcium) | 19.37 | 36.42% | 12.32 | 16.11 | 23.53% |
| Rosuvastatin | Oral | Tablet 20 mg (as calcium) | 27.58 | 36.42% | 17.54 | 22.93 | 23.51% |
| Rosuvastatin | Oral | Tablet 40 mg (as calcium) | 39.33 | 36.42% | 25.01 | 32.71 | 23.54% |
| Rosuvastatin | Oral | Tablet 5 mg (as calcium) | 13.20 | 36.42% | 8.39 | 10.97 | 23.52% |
| Roxithromycin | Oral | Tablet 150 mg | 1.78 | 12.16% | 1.56 | 1.78 | 12.36% |
| Roxithromycin | Oral | Tablet 300 mg | 1.78 | 12.16% | 1.56 | 1.78 | 12.36% |
| Sildenafil | Oral | Tablet 20 mg (as citrate) | 754.68 | 23.94% | 574.01 | 754.68 | 23.94% |
| Simvastatin | Oral | Tablet 10 mg | 1.77 | 21.91% | 1.38 | 1.77 | 22.03% |
| Simvastatin | Oral | Tablet 20 mg | 2.56 | 21.91% | 2.00 | 2.56 | 21.88% |
| Simvastatin | Oral | Tablet 40 mg | 3.68 | 21.91% | 2.87 | 3.68 | 22.01% |
| Simvastatin | Oral | Tablet 5 mg | 1.28 | 21.91% | 1.00 | 1.28 | 21.88% |
| Simvastatin | Oral | Tablet 80 mg | 5.28 | 21.91% | 4.12 | 5.28 | 21.97% |
| Sodium chloride | Injection | I.V. infusion 154 mmol per L, 1 L | 1.37 | 12.40% | 1.20 | 1.37 | 12.41% |
| Tacrolimus | Oral | Capsule 0.5 mg | 163.92 | 23.70% | 125.07 | 146.89 | 14.85% |
| Tacrolimus | Oral | Capsule 0.5 mg (once daily prolonged release) | 49.18 | 23.70% | 37.52 | 44.07 | 14.86% |
| Tacrolimus | Oral | Capsule 1 mg | 327.84 | 23.70% | 250.14 | 293.78 | 14.85% |
| Tacrolimus | Oral | Capsule 1 mg (once daily prolonged release) | 196.70 | 23.70% | 150.08 | 176.26 | 14.85% |
| Tacrolimus | Oral | Capsule 5 mg | 819.19 | 23.70% | 625.04 | 734.08 | 14.85% |
| Tacrolimus | Oral | Capsule 5 mg (once daily prolonged release) | 491.77 | 23.70% | 375.22 | 440.68 | 14.85% |
| Telmisartan | Oral | Tablet 40 mg | 5.27 | 28.90% | 3.75 | 5.27 | 28.84% |
| Telmisartan | Oral | Tablet 80 mg | 15.28 | 28.90% | 10.86 | 15.28 | 28.93% |
| Telmisartan with hydrochlorothiazide | Oral | Tablet 40 mg-12.5 mg | 6.68 | 21.39% | 5.25 | 6.68 | 21.41% |
| Telmisartan with hydrochlorothiazide | Oral | Tablet 80 mg-12.5 mg | 16.69 | 21.39% | 13.12 | 16.69 | 21.39% |
| Telmisartan with hydrochlorothiazide | Oral | Tablet 80 mg-25 mg | 18.10 | 21.39% | 14.23 | 18.10 | 21.38% |
| Temozolomide | Oral | Capsule 100 mg | 379.66 | 37.73% | 236.41 | 309.47 | 23.61% |
| Temozolomide | Oral | Capsule 140 mg | 523.58 | 37.73% | 326.03 | 426.79 | 23.61% |
| Temozolomide | Oral | Capsule 180 mg | 634.01 | 37.73% | 394.80 | 540.72 | 26.99% |
| Temozolomide | Oral | Capsule 20 mg | 88.62 | 37.73% | 55.18 | 72.24 | 23.62% |
| Temozolomide | Oral | Capsule 250 mg | 902.03 | 37.73% | 561.69 | 735.27 | 23.61% |
| Temozolomide | Oral | Capsule 5 mg | 30.15 | 37.73% | 18.77 | 24.57 | 23.61% |
| Tramadol | Injection | Injection containing tramadol hydrochloride 100 mg in 2 mL | 4.65 | 20.51% | 3.70 | 4.18 | 11.48% |
| Valaciclovir | Oral | Tablet 500 mg (as hydrochloride) | 18.26 | 41.74% | 10.64 | 12.12 | 12.21% |
| Vancomycin | Injection | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | 3.24 | 11.12% | 2.88 | 3.24 | 11.11% |
| Vancomycin | Injection | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | 1.61 | 11.12% | 1.43 | 1.61 | 11.18% |
| Venlafaxine | Oral | Capsule (modified release) 150 mg (as hydrochloride) | 12.53 | 37.76% | 7.80 | 9.75 | 20.00% |
| Venlafaxine | Oral | Capsule (modified release) 37.5 mg (as hydrochloride) | 5.82 | 37.76% | 3.62 | 4.53 | 20.09% |
| Venlafaxine | Oral | Capsule (modified release) 75 mg (as hydrochloride) | 10.27 | 37.76% | 6.39 | 8.00 | 20.13% |
| Vinorelbine | Injection | Solution for I.V. infusion 10 mg (as tartrate) in 1 mL | 12.64 | 32.37% | 8.55 | 10.65 | 19.72% |
| Vinorelbine | Injection | Solution for I.V. infusion 50 mg (as tartrate) in 5 mL | 52.74 | 32.37% | 35.67 | 44.43 | 19.72% |
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with no reduction, are in the legal determination on the ComLaw website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2015 PBS approved ex-manufacturer price and the weighted average disclosed price for the 2015 October Cycle was below 10%. A new brand listed after 31 March 2015 for a pharmaceutical item that has an existing brand with a determination in Schedule 1 of the determination will also take the reduction on 1 October 2015 under section 99ADHA of the Act.
Amendments have been made to the legal instrument for October 2015 price disclosure reductions to reflect outcomes from disputes following submission of amended data by some companies and to prevent a decrease in price for brands of five chemotherapy drugs that had price increases approved or received a recommendation to have their current price maintained. The amendments are reflected in the table above.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEST on Thursday, 25 June 2015.
